By Fineline Cube Betta Pharmaceuticals (SHE: 300558) announced that ensartinib (trade name: Ensacove) has been approved by China’s National Medical Products Administration (NMPA) for a new indication: adjuvant therapy for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB who have previously undergone surgical resection, regardless of whether adjuvant chemotherapy is determined by the physician as indicated or not. This marks the third indication for ensartinib approved in China, extending the drug from advanced disease into the curative-intent early-stage setting.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | National Medical Products Administration (NMPA), China |
| Approval Type | New indication approval |
| Product | ensartinib (Ensacove) |
| New Indication | Adjuvant therapy for ALK-positive NSCLC (stages IB–IIIB) after surgical resection, irrespective of physician-determined adjuvant chemotherapy indication |
| Date | 03 Sept 2026 |
| Indication Count | Third approved indication in China |
Drug Profile & Approval History
- Molecule: ensartinib, a novel, potent and highly selective next-generation ALK inhibitor developed by Betta Pharmaceuticals
- Approval History in China:
- 2020 – Second-line treatment of ALK-positive NSCLC
- 2022 – First-line treatment of ALK-positive NSCLC
- 2026 – Adjuvant therapy for resected ALK-positive NSCLC (stages IB–IIIB)
- Strategic Significance: The adjuvant approval completes ensartinib’s coverage across the treatment continuum — from advanced disease lines into the curative-intent setting
Clinical Evidence – Adjuvant Therapy Study
| Endpoint | Result | Interpretation |
|---|---|---|
| 2-year disease-free survival (DFS) rate | 86.4% | High sustained DFS at 2 years |
| Hazard ratio (HR) | 0.20 | Represents an 80% reduction in the risk of recurrence |
The clinical study underpinning the approval demonstrated that ensartinib adjuvant therapy achieved a 2-year DFS rate of 86.4% with a hazard ratio of 0.20 — translating into an 80% reduction in the risk of recurrence for resected ALK-positive NSCLC patients. The broad label, covering patients both with and without a physician-determined indication for adjuvant chemotherapy, maximizes the eligible population.
Market Impact & Outlook
- Early-stage expansion: Moving into adjuvant therapy opens a substantially larger and earlier patient population for ensartinib, where treatment duration and commercial value typically exceed late-line settings
- Broad label advantage: Inclusion of chemotherapy-indicated and chemotherapy-non-indicated patients gives clinicians flexibility and widens commercial reach versus more restrictive adjuvant labels
- Competitive landscape: The 80% recurrence risk reduction positions ensartinib strongly against other ALK inhibitors seeking to establish adjuvant credentials in China
- Lifecycle value: A third indication reinforces Betta Pharmaceuticals’ (SHE: 300558) flagship oncology asset and extends its relevance as the ALK-positive NSCLC market shifts earlier in the disease course
Forward‑Looking Statements: This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug commercialization, indication adoption and market potential are forward-looking and subject to risks and uncertainties, including competitive developments, reimbursement outcomes and clinical practice patterns. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.-Fineline Info & Tech